KR20230017192A - 경질 캡슐 투여 형태 및 이의 용도 - Google Patents

경질 캡슐 투여 형태 및 이의 용도 Download PDF

Info

Publication number
KR20230017192A
KR20230017192A KR1020227041029A KR20227041029A KR20230017192A KR 20230017192 A KR20230017192 A KR 20230017192A KR 1020227041029 A KR1020227041029 A KR 1020227041029A KR 20227041029 A KR20227041029 A KR 20227041029A KR 20230017192 A KR20230017192 A KR 20230017192A
Authority
KR
South Korea
Prior art keywords
hydroxyvitamin
dosage form
hard capsule
optionally
hard
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041029A
Other languages
English (en)
Korean (ko)
Inventor
림 엘라메인 엘시디그
콜름 눌티
Original Assignee
에어젠 파마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000220 external-priority patent/WO2021205225A1/en
Application filed by 에어젠 파마 엘티디. filed Critical 에어젠 파마 엘티디.
Publication of KR20230017192A publication Critical patent/KR20230017192A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227041029A 2020-05-31 2021-05-31 경질 캡슐 투여 형태 및 이의 용도 Pending KR20230017192A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection
IBPCT/IB2021/000220 2021-04-06
PCT/IB2021/000376 WO2021245458A1 (en) 2020-05-31 2021-05-31 Hard capsule dosage form and uses thereof

Publications (1)

Publication Number Publication Date
KR20230017192A true KR20230017192A (ko) 2023-02-03

Family

ID=78831505

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041029A Pending KR20230017192A (ko) 2020-05-31 2021-05-31 경질 캡슐 투여 형태 및 이의 용도

Country Status (9)

Country Link
US (2) US20230293552A1 (https=)
EP (1) EP4157231A1 (https=)
JP (1) JP2023526980A (https=)
KR (1) KR20230017192A (https=)
CN (2) CN120694962A (https=)
AU (1) AU2021285494A1 (https=)
CA (1) CA3181945A1 (https=)
IL (1) IL297885A (https=)
WO (1) WO2021245458A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途
CN119907688A (zh) * 2022-09-20 2025-04-29 比利时胶囊公司 含有氧化镁的遮光硬胶囊
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) * 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
CN101595133B (zh) * 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
HUE073014T2 (hu) * 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
EP2321273B1 (en) * 2008-07-24 2014-11-19 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
US8852631B2 (en) * 2009-09-24 2014-10-07 Capsugel Belgium Nv Acid resistant capsules
KR20140072715A (ko) * 2012-12-05 2014-06-13 삼성정밀화학 주식회사 경질 캡슐
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) * 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
BR112020000011A2 (pt) * 2017-07-11 2020-07-21 Qualicaps Co., Ltd. cápsula dura entérica
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法
US20210308151A1 (en) * 2020-04-06 2021-10-07 Eirgen Pharma Ltd. Activating endogenous antimicrobials to treat sars-cov-2 infection
CN120694962A (zh) * 2020-05-31 2025-09-26 艾尔金制药有限公司 硬胶囊剂型和其用途

Also Published As

Publication number Publication date
CN115768412A (zh) 2023-03-07
WO2021245458A1 (en) 2021-12-09
CN120694962A (zh) 2025-09-26
EP4157231A1 (en) 2023-04-05
US20230293552A1 (en) 2023-09-21
AU2021285494A1 (en) 2022-12-08
JP2023526980A (ja) 2023-06-26
US20230330110A1 (en) 2023-10-19
CA3181945A1 (en) 2021-12-09
IL297885A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
TWI659753B (zh) 經穩定之修飾釋放維他命ｄ調配物及其服用方法
JP5894717B2 (ja) 乱用抑止性製剤
US20230330110A1 (en) Hard capsule dosage form and uses thereof
JP7603000B2 (ja) ビタミンｄ小児用剤形、製造方法および使用方法
JP2013520514A (ja) 濫用耐性製剤
CN107405309A (zh) 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物
JP2013526523A (ja) メトプロロールを含むアルコール耐性持続放出性経口剤形
TWI645864B (zh) 經穩定之修飾釋放維他命ｄ調配物及其服用方法
TWI812891B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
TWI743426B (zh) 經穩定之修飾釋放維他命d調配物及其服用方法
EA052626B1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
NZ711924B2 (en) Stabilized modified release vitamin d formulation and method of administering same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240530

Comment text: Request for Examination of Application